Almeida, Anderson Rodrigues de 
; Dantas, Andréa Tavares; Gonçalves, Maria Eduarda de Oliveira; Chêne, Charlotte ; Jeljeli, Mohamed ; Chouzenoux, Sandrine ; Thomas, Marine; Cunha, Eudes Gustavo Constantino ; Valadares, Lilian David de Azevedo ; Gomes, João Victor de Melo ; Paula, Simão Kalebe Silva de ; Pitta, Marina Galdino da Rocha ; Pitta, Ivan da Rocha ; Rêgo, Moacyr Jesus Barreto de Melo ; Pereira, Michelly Cristiny ; Duarte, Angela Luzia Branco Pinto; Abdalla, Dulcinéia Saes Parra ; Nicco, Carole ; Batteux, Frédéric ; Pitta, Maira Galdino da Rocha
Source: Inflammopharmacology. Unidade: FCF
Subjects: FIBROSE PULMONAR, CITOCINAS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
ALMEIDA, Anderson Rodrigues de et al. PPARγ partial agonist LPSF/GQ-16 prevents dermal and pulmonary fibrosis in HOCl-induced systemic sclerosis (SSc) and modulates cytokine production in PBMC of SSc patients. Inflammopharmacology, v. 32, p. 433-446, 2024Tradução . . Disponível em: https://doi.org/10.1007/s10787-023-01296-9. Acesso em: 06 nov. 2024.APA
Almeida, A. R. de, Dantas, A. T., Gonçalves, M. E. de O., Chêne, C., Jeljeli, M., Chouzenoux, S., et al. (2024). PPARγ partial agonist LPSF/GQ-16 prevents dermal and pulmonary fibrosis in HOCl-induced systemic sclerosis (SSc) and modulates cytokine production in PBMC of SSc patients. Inflammopharmacology, 32, 433-446. doi:10.1007/s10787-023-01296-9NLM
Almeida AR de, Dantas AT, Gonçalves ME de O, Chêne C, Jeljeli M, Chouzenoux S, Thomas M, Cunha EGC, Valadares LD de A, Gomes JV de M, Paula SKS de, Pitta MG da R, Pitta I da R, Rêgo MJB de M, Pereira MC, Duarte ALBP, Abdalla DSP, Nicco C, Batteux F, Pitta MG da R. PPARγ partial agonist LPSF/GQ-16 prevents dermal and pulmonary fibrosis in HOCl-induced systemic sclerosis (SSc) and modulates cytokine production in PBMC of SSc patients [Internet]. Inflammopharmacology. 2024 ; 32 433-446.[citado 2024 nov. 06 ] Available from: https://doi.org/10.1007/s10787-023-01296-9Vancouver
Almeida AR de, Dantas AT, Gonçalves ME de O, Chêne C, Jeljeli M, Chouzenoux S, Thomas M, Cunha EGC, Valadares LD de A, Gomes JV de M, Paula SKS de, Pitta MG da R, Pitta I da R, Rêgo MJB de M, Pereira MC, Duarte ALBP, Abdalla DSP, Nicco C, Batteux F, Pitta MG da R. PPARγ partial agonist LPSF/GQ-16 prevents dermal and pulmonary fibrosis in HOCl-induced systemic sclerosis (SSc) and modulates cytokine production in PBMC of SSc patients [Internet]. Inflammopharmacology. 2024 ; 32 433-446.[citado 2024 nov. 06 ] Available from: https://doi.org/10.1007/s10787-023-01296-9
